# Stereotactic Body Radiation Therapy, Tremelimumab and Durvalumab in Treating Participants With Recurrent or Metastatic Cervical, Vaginal, or Vulvar Cancers

> **NCT03452332** · PHASE1 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 20 (actual)

## Conditions studied

- Advanced Cervical Adenocarcinoma
- Advanced Vaginal Carcinoma
- Advanced Vulvar Carcinoma
- Human Papillomavirus-Related Cervical Squamous Cell Carcinoma
- Human Papillomavirus-Related Vulvar Squamous Cell Carcinoma
- Metastatic Cervical Adenocarcinoma
- Metastatic Cervical Carcinoma
- Metastatic Cervical Squamous Cell Carcinoma, Not Otherwise Specified
- Metastatic Vaginal Adenocarcinoma
- Metastatic Vaginal Carcinoma
- Metastatic Vulvar Carcinoma
- Recurrent Cervical Adenocarcinoma
- Recurrent Cervical Carcinoma
- Recurrent Cervical Squamous Cell Carcinoma, Not Otherwise Specified
- Recurrent Vaginal Carcinoma
- Recurrent Vulvar Carcinoma
- Stage III Cervical Cancer AJCC v8
- Stage III Vaginal Cancer AJCC v8
- Stage III Vulvar Cancer AJCC v8
- Stage IIIA Cervical Cancer AJCC v8
- Stage IIIA Vulvar Cancer AJCC v8
- Stage IIIB Cervical Cancer AJCC v8
- Stage IIIB Vulvar Cancer AJCC v8
- Stage IIIC Vulvar Cancer AJCC v8
- Stage IV Cervical Cancer AJCC v8
- Stage IV Vaginal Cancer AJCC v8
- Stage IV Vulvar Cancer AJCC v8
- Stage IVA Cervical Cancer AJCC v8
- Stage IVA Vaginal Cancer AJCC v8
- Stage IVA Vulvar Cancer AJCC v8
- Stage IVB Cervical Cancer AJCC v8
- Stage IVB Vaginal Cancer AJCC v8
- Stage IVB Vulvar Cancer AJCC v8
- Vaginal Squamous Cell Carcinoma, Not Otherwise Specified
- Vulvar Adenocarcinoma
- Vulvar Squamous Cell Carcinoma

## Interventions

- **BIOLOGICAL:** Durvalumab
- **OTHER:** Laboratory Biomarker Analysis
- **RADIATION:** Stereotactic Radiosurgery
- **BIOLOGICAL:** Tremelimumab

## Key facts

- **NCT ID:** NCT03452332
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-07-18
- **Primary completion:** 2023-08-11
- **Final completion:** 2023-08-11
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2023-09-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03452332

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03452332, "Stereotactic Body Radiation Therapy, Tremelimumab and Durvalumab in Treating Participants With Recurrent or Metastatic Cervical, Vaginal, or Vulvar Cancers". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03452332. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*